The Kolling Institute Tumour Bank

Located on the Royal North Shore Hospital, the Kolling Institute Tumour Bank (KITB) is a collection of human biospecimens that are stored and distributed for use in cancer research. It is partially funded by the Sydney Vital grant (2017-2019) from the Cancer Institute NSW (CINSW), supporting two of the current four positions working as part of our Tumour Bank. The Kolling Institute Tumour Bank is certified by the NSW Health Pathology Biobank Certification Program (BRC-00015).

The KITB consists of collections of breast, gynaecological, upper gastrointestinal, endocrine and neurological tumours. In 2017, colorectal specimens were added to this collection. There is also a Healthy Volunteers blood bank. There are currently over 20,000 specimens collected as part of the KITB from over 9,000 cancer patients who have had cancer surgery at Royal North Shore Hospital, North Shore Private or The Mater Hospital, North Sydney with approval from the relevant Human Research Ethics Committees (HRECs). This is an invaluable resource that facilitates translational research now and into the future as new technological platforms become available.

In 2017-18, the KITB is working closely with NSW Health Pathology to develop streamlined approaches to tumour banking by further embedding biobanking processes within Anatomical Pathology laboratories. The KITB is also working as part of the CINSW Biobanking Stakeholder Network on a project to explore data linkage for the clinical annotation of biospecimens.

Tumour Banking for Future Research

KITB Team (L->R): Ussha Pillai, Mikaela Holmes, Shannon Chan and Sam Yuen

The KITB is one of the oldest tumour banks established in NSW.

  • 1992 the KITB was established by Professors Bruce Robinson and Leigh Delbridge. The first collections were endocrine tumours (thyroid, parathyroid and adrenal tumours), reflecting the research interests of these professors.
  • 2001 – Professors Ross Smith and Thomas Hugh began to collect upper gastrointestinal tumours (liver, pancreas and stomach tumours).
  • 2002 – Professor Bruce Robinson and Dr Ray Cook established a collection of neurological (brain and pituitary) tumours.
  • 2004 – the KITB expanded into breast and gynaecological (ovarian, endometrial and cervical) tumour collections with the research interests of Professors Robert Baxter and Deborah Marsh, respectively.
  • 2005 – the Healthy Volunteers collection was established by Professor Deborah Marsh as a means for researchers to compare the differences between normal, healthy blood and blood from cancer patients.
  • 2006 – the KITB became a funded collection node of the Australian Breast Cancer Tissue Bank.
  • 2017 – the KITB began collecting colorectal tumours and rolled all informed consenting literature and forms under the one umbrella protocol, allowing all cancer types to be collected.

Abraham, D., Jackson, N., Gundara, J. S., Zhao, J., Gill, A. J., Delbridge, L., . . . Sidhu, S. B. (2011). MicroRNA Profiling of Sporadic and Hereditary Medullary Thyroid Cancer Identifies Predictors of Nodal Metastasis, Prognosis, and Potential Therapeutic Targets. Clinical Cancer Research, 17(14), 4772.

Agrawal, N., Jiao, Y., Sausen, M., Leary, R., Bettegowda, C., Roberts, N. J., . . . Ball, D. W. (2013). Exomic Sequencing of Medullary Thyroid Cancer Reveals Dominant and Mutually Exclusive Oncogenic Mutations in RET and RAS. The Journal of Clinical Endocrinology and Metabolism, 98(2), E364-E369. doi:10.1210/jc.2012-2703

Åkerström, T., Crona, J., Delgado Verdugo, A., Starker, L. F., Cupisti, K., Willenberg, H. S., . . . Björklund, P. (2012). Comprehensive Re-Sequencing of Adrenal Aldosterone Producing Lesions Reveal Three Somatic Mutations near the KCNJ5 Potassium Channel Selectivity Filter. PLOS ONE, 7(7), e41926. doi:10.1371/journal.pone.0041926

Au, A. Y. M., McDonald, K., Gill, A., Sywak, M., Diamond, T., Conigrave, A. D., & Clifton-Bligh, R. J. (2008). PTH Mutation with Primary Hyperparathyroidism and Undetectable Intact PTH. New England Journal of Medicine, 359(11), 1184-1186. doi:10.1056/NEJMc0802570

Barnetson, R., Eckstein, R., Robinson, B., & Schnitzler, M. (2003). There is no increase in frequency of somatic mutations in metastases compared with primary colorectal carcinomas with microsatellite instability. Genes, Chromosomes and Cancer, 38(2), 149-156. doi:10.1002/gcc.10262

Barnetson, R., Jass, J., Tse, R., Eckstein, R., Robinson, B., & Schnitzler, M. (2000). Mutations associated with microsatellite unstable colorectal carcinomas exhibit widespread intratumoral heterogeneity. Genes Chromosomes Cancer, 29(2), 130-136.

Barnetson, R. A., Symons, P., Robinson, B. G., & Schnitzler, M. (2000). Genetic analysis of multiple sporadic colon carcinomas from a single patient. Int J Colorectal Dis, 15(2), 83-86.

Benn, D. E., Croxson, M. S., Tucker, K., Bambach, C. P., Richardson, A. L., Delbridge, L., . . . Robinson, B. G. (2003). Novel succinate dehydrogenase subunit B (SDHB) mutations in familial phaeochromocytomas and paragangliomas, but an absence of somatic SDHB mutations in sporadic phaeochromocytomas. Oncogene, 22(9), 1358-1364.

Benn, D. E., Dwight, T., Richardson, A. L., Delbridge, L., Bambach, C. P., Stowasser, M., . . . Robinson, B. G. (2000). Sporadic and Familial Pheochromocytomas Are Associated with Loss of at Least Two Discrete Intervals on Chromosome 1p. Cancer Research, 60(24), 7048.

Bullock, M., Duncan, E. L., O’Neill, C., Tacon, L., Sywak, M., Sidhu, S., . . . Clifton-Bligh, R. J. (2012). Association of FOXE1 Polyalanine Repeat Region with Papillary Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism, 97(9), E1814-E1819. doi:10.1210/jc.2012-1456

Bullock, M., Lim, G., Li, C., Choi, I. H., Kochhar, S., Liddle, C., . . . Clifton-Bligh, R. J. (2016). Thyroid transcription factor FOXE1 interacts with ETS factor ELK1 to co-regulate TERT. Oncotarget, 7(52), 85948-85962. doi:10.18632/oncotarget.13288

Cavalli, F. M. G., Remke, M., Reimand, J., Rampasek, L., Goldenberg, A., Taylor, M., & Ramaswamy, V. (2016). MB-87 integrated genomics reveals novel subtypes of medulloblastoma subgroups. Neuro-Oncology, 18(Suppl 3), iii116-iii117. doi:10.1093/neuonc/now076.83

Chung, L., Moore, K., Phillips, L., Boyle, F. M., Marsh, D. J., & Baxter, R. C. (2014). Novel serum protein biomarker panel revealed by mass spectrometry and its prognostic value in breast cancer. Breast Cancer Research : BCR, 16(3), R63-R63. doi:10.1186/bcr3676

Chung, L., Shibli, S., Moore, K., Elder, E. E., Boyle, F. M., Marsh, D. J., & Baxter, R. C. (2013). Tissue biomarkers of breast cancer and their association with conventional pathologic features. British Journal of Cancer, 108(2), 351-360. doi:10.1038/bjc.2012.552

Cole, A. J., Dwight, T., Gill, A. J., Dickson, K.-A., Zhu, Y., Clarkson, A., . . . Marsh, D. J. (2016). Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing. Scientific Reports, 6, 26191. doi:10.1038/srep26191

https://www.nature.com/articles/srep26191#supplementary-information

Cole, A. J., Zhu, Y., Dwight, T., Yu, B., Dickson, K.-A., Gard, G. B., . . . Marsh, D. J. (2017). Comprehensive analyses of somatic TP53 mutation in tumors with variable mutant allele frequency. Scientific Data, 4, 170120. doi:10.1038/sdata.2017.120

Dahia, P. L. M., Ross, K. N., Wright, M. E., Hayashida, C. Y., Santagata, S., Barontini, M., . . . Stiles, C. D. (2005). A HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas. PLoS Genetics, 1(1), 72-80. doi:10.1371/journal.pgen.0010008

Dwight, T., Kytola, S., Teh, B., Theodosopoulos, G., Richardson, A., Philips, J., . . . Robinson, B. (2002). Genetic analysis of lithium-associated parathyroid tumors. European Journal of Endocrinology, 146(5), 619-627. doi:10.1530/eje.0.1460619

Dwight, T., Na, U., Kim, E., Zhu, Y., Richardson, A. L., Robinson, B. G., . . . Winge, D. R. (2017). Analysis of SDHAF3 in familial and sporadic pheochromocytoma and paraganglioma. BMC Cancer, 17, 497. doi:10.1186/s12885-017-3486-z

Dwight, T., Nelson, A. E., Theodosopoulos, G., Richardson, A. L., Learoyd, D. L., Philips, J., . . . Robinson, B. G. (2002). Independent Genetic Events Associated with the Development of Multiple Parathyroid Tumors in Patients with Primary Hyperparathyroidism. The American Journal of Pathology, 161(4), 1299-1306.

Dwight, T., Twigg, S., Delbridge, L., Wong, F.-K., Farnebo, F., Richardson, A. L., . . . Robinson, B. (2000). Loss of heterozygosity in sporadic parathyroid tumours: involvement of chromosome 1 and the MEN1 gene locus in 11q13. Clinical Endocrinology, 53(1), 85-92. doi:10.1046/j.1365-2265.2000.01010.x

Elston, M. S., Gill, A. J., Conaglen, J. V., Clarkson, A., Cook, R. J., Little, N. S., . . . McDonald, K. L. (2009). Nuclear Accumulation of E-Cadherin Correlates with Loss of Cytoplasmic Membrane Staining and Invasion in Pituitary Adenomas. The Journal of Clinical Endocrinology & Metabolism, 94(4), 1436-1442. doi:10.1210/jc.2008-2075

Elston, M. S., Gill, A. J., Conaglen, J. V., Clarkson, A., Shaw, J. M., Law, A. J. J., . . . McDonald, K. L. (2008). Wnt Pathway Inhibitors Are Strongly Down-Regulated in Pituitary Tumors. Endocrinology, 149(3), 1235-1242. doi:10.1210/en.2007-0542

Flynn, A., Benn, D., Clifton-Bligh, R., Robinson, B., Trainer, A. H., James, P., . . . Tothill, R. W. (2015). The genomic landscape of phaeochromocytoma. The Journal of Pathology, 236(1), 78-89. doi:10.1002/path.4503

Flynn, A., Dwight, T., Benn, D., Deb, S., Colebatch, A. J., Fox, S., . . . Tothill, R. W. (2017). Cousins not twins: intratumoural and intertumoural heterogeneity in syndromic neuroendocrine tumours. J Pathol, 242(3), 273-283. doi:10.1002/path.4900

Foukakis, T., Au, A. Y. M., Wallin, G. r., Geli, J., Forsberg, L., Clifton-Bligh, R., . . . Larsson, C. (2006). The Ras Effector NORE1A Is Suppressed in Follicular Thyroid Carcinomas with a PAX8-PPARγ Fusion. The Journal of Clinical Endocrinology & Metabolism, 91(3), 1143-1149. doi:10.1210/jc.2005-1372

Gill, A. J., Chou, A., Vilain, R., Clarkson, A., Lui, M., Jin, R., . . . Clifton-Bligh, R. J. (2010). Immunohistochemistry for SDHB Divides Gastrointestinal Stromal Tumors (GISTs) into 2 Distinct Types. The American Journal of Surgical Pathology, 34(5), 636-644. doi:10.1097/PAS.0b013e3181d6150d

Gill, A. J., Clarkson, A., Gimm, O., Keil, J., Dralle, H., Howell, V. M., & Marsh, D. J. (2006). Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. The American Journal of Surgical Pathology, 30(9), 1140-1149. doi:10.1097/01.pas.0000209827.39477.4f

Gill, A. J., Johns, A. L., Eckstein, R., Samra, J. S., Kaufman, A., Chang, D. K., . . . Kench, J. G. (2009). Synoptic reporting improves histopathological assessment of pancreatic resection specimens. Pathology, 41(2), 161-167. doi:http://dx.doi.org/10.1080/00313020802337329

Gimm, O., Perren, A., Weng, L.-P., Marsh, D. J., Yeh, J. J., Ziebold, U., . . . Eng, C. (2000). Differential Nuclear and Cytoplasmic Expression of PTEN in Normal Thyroid Tissue, and Benign and Malignant Epithelial Thyroid Tumors. The American Journal of Pathology, 156(5), 1693-1700.

Giordano, T. J., Au, A. Y. M., Kuick, R., Thomas, D. G., Rhodes, D. R., Wilhelm, K. G., . . . Koenig, R. J. (2006). Delineation, Functional Validation, and Bioinformatic Evaluation of Gene Expression in Thyroid Follicular Carcinomas with the <em>PAX8-PPARG</em> Translocation. Clinical Cancer Research, 12(7), 1983.

Glover, A. R., Zhao, J. T., Gill, A. J., Weiss, J., Mugridge, N., Kim, E., . . . Sidhu, S. B. (2015). MicroRNA-7 as a tumor suppressor and novel therapeutic for adrenocortical carcinoma. Oncotarget, 6(34), 36675-36688.

Glover, A. R., Zhao, J. T., Ip, J. C., Lee, J. C., Robinson, B. G., Gill, A. J., . . . Sidhu, S. B. (2015). Long noncoding RNA profiles of adrenocortical cancer can be used to predict recurrence. Endocrine-Related Cancer, 22(1), 99-109. doi:10.1530/erc-14-0457

Gordon, C. M., Majzoub, J. A., Marsh, D. J., Mulliken, J. B., Ponder, B. A. J., Robinson, B. G., & Eng, C. (1998). Four Cases of Mucosal Neuroma Syndrome: Multiple Endocrine Neoplasm 2B or Not 2B?1. The Journal of Clinical Endocrinology & Metabolism, 83(1), 17-20. doi:10.1210/jcem.83.1.4504

Gundara, J. S., Zhao, J. T., Gill, A. J., Clifton-Bligh, R., Robinson, B. G., Delbridge, L., & Sidhu, S. B. (2014). Nodal metastasis microRNA expression correlates with the primary tumour in MTC. ANZ Journal of Surgery, 84(4), 235-239. doi:10.1111/j.1445-2197.2012.06291.x

Hahn, M. A., Howell, V. M., Gill, A. J., Clarkson, A., Weaire-Buchanan, G., Robinson, B. G., . . . Marsh, D. J. (2010). CDC73/HRPT2 CpG island hypermethylation and mutation of 5′-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors. Endocrine-Related Cancer, 17(1), 273-282. doi:10.1677/erc-09-0291

Hahn, M. A., McDonnell, J., & Marsh, D. J. (2009). The effect of disease-associated HRPT2 mutations on splicing. Journal of Endocrinology, 201(3), 387-396. doi:10.1677/joe-09-0038

Haven, C. J., Howell, V. M., Eilers, P. H. C., Dunne, R., Takahashi, M., van Puijenbroek, M., . . . Teh, B. T. (2004). Gene Expression of Parathyroid Tumors. Cancer Research, 64(20), 7405.

Howell, V., Haven, C., Kahnoski, K., Khoo, S., Petillo, D., Chen, J., . . . Teh, B. (2003). HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. Journal of Medical Genetics, 40(9), 657-663. doi:10.1136/jmg.40.9.657

Howell, V. M., Cardinal, J. W., Richardson, A.-L., Gimm, O., Robinson, B. G., & Marsh, D. J. (2006). Rapid Mutation Screening for HRPT2 and MEN1 Mutations Associated with Familial and Sporadic Primary Hyperparathyroidism. The Journal of molecular diagnostics : JMD, 8(5), 559-566. doi:10.2353/jmoldx.2006.060015

Howell, V. M., Gill, A., Clarkson, A., Nelson, A. E., Dunne, R., Delbridge, L. W., . . . Marsh, D. J. (2009). Accuracy of Combined Protein Gene Product 9.5 and Parafibromin Markers for Immunohistochemical Diagnosis of Parathyroid Carcinoma. The Journal of Clinical Endocrinology & Metabolism, 94(2), 434-441. doi:10.1210/jc.2008-1740

Hudson, A. L., Parker, N. R., Khong, P., Parkinson, J. F., Dwight, T., Ikin, R. J., . . . Howell, V. M. (2018). Glioblastoma Recurrence Correlates With Increased APE1 and Polarization Toward an Immuno-Suppressive Microenvironment. Frontiers in Oncology, 8, 314. doi:10.3389/fonc.2018.00314

Ip, J., Pang, T., Pon, C., Zhao, J. T., Sywak, M., Gill, A., . . . Sidhu, S. (2013). Mutations in KCNJ5 determines presentation and likelihood of cure in primary hyperaldosteronism: KCNJ5 mutations and primary hyperaldosteronism (Vol. 85).

Ip, J. C. Y., Pang, T. C. Y., Pon, C. K., Zhao, J. T., Sywak, M. S., Gill, A. J., . . . Sidhu, S. B. (2015). Mutations in KCNJ5 determines presentation and likelihood of cure in primary hyperaldosteronism. ANZ Journal of Surgery, 85(4), 279-283. doi:10.1111/ans.12470

Kan, C. W. S., Hahn, M. A., Gard, G. B., Maidens, J., Huh, J. Y., Marsh, D. J., & Howell, V. M. (2012). Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer. BMC Cancer, 12, 627-627. doi:10.1186/1471-2407-12-627

Kim, E., Rath, E. M., Tsang, V. H. M., Duff, A. P., Robinson, B. G., Church, W. B., . . . Clifton-Bligh, R. J. (2015). Structural and functional consequences of succinate dehydrogenase subunit B mutations. Endocrine-Related Cancer, 22(3), 387-397. doi:10.1530/erc-15-0099

Kuo, S. C. L., Gananadha, S., Scarlett, C. J., Gill, A., & Smith, R. C. (2008). Sporadic Pancreatic Polypeptide Secreting Tumors (PPomas) of the Pancreas. World Journal of Surgery, 32(8), 1815-1822. doi:10.1007/s00268-008-9499-7

Lee, J. C., Zhao, J. T., Clifton-Bligh, R. J., Gill, A., Gundara, J. S., Ip, J. C., . . . Sidhu, S. B. (2013). MicroRNA-222 and MicroRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer. Cancer, 119(24), 4358-4365. doi:10.1002/cncr.28254

Lee, J.-J., Au, A. Y. M., Foukakis, T., Barbaro, M., Kiss, N., Clifton-Bligh, R., . . . Larsson, C. (2008). Array-CGH identifies cyclin D1 and UBCH10 amplicons in anaplastic thyroid carcinoma. Endocrine-Related Cancer, 15(3), 801-815. doi:10.1677/erc-08-0018

Marsh, D. J., Andrew, S. D., Eng, C., Learoyd, D. L., Capes, A. G., Pojer, R., . . . Robinson, B. G. (1996). Germline and Somatic Mutations in an Oncogene: <em>RET</em> Mutations in Inherited Medullary Thyroid Carcinoma. Cancer Research, 56(6), 1241.

Marsh, D. J., Andrew, S. D., Learoyd, D. L., Pojer, R., Eng, C., & Robinson, B. G. (1998). Deletion-insertion mutation encompassing RET codon 634 is associated with medullary thyroid carcinoma. Human Mutation, 11(S1), S3-S4. doi:10.1002/humu.1380110102

Marsh, D. J., Dahia, P. L., Coulon, V., Zheng, Z., Dorion-Bonnet, F., Call, K. M., . . . Eng, C. (1998). Allelic imbalance, including deletion of PTEN/MMACI, at the Cowden disease locus on 10q22-23, in hamartomas from patients with Cowden syndrome and germline PTEN mutation. Genes Chromosomes Cancer, 21(1), 61-69.

Marsh, D. J., Learoyd, D. L., Andrew, S. D., Krishnan, L., Pojer, R., Richardson, A.-L., . . . Robinson, B. G. (1996). Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clinical Endocrinology, 44(3), 249-257. doi:10.1046/j.1365-2265.1996.681503.x

Marsh, D. J., Theodosopoulos, G., Martin-Schulte, K., Richardson, A.-L., Philips, J., Röher, H.-D., . . . Robinson, B. G. (2003). Genome-Wide Copy Number Imbalances Identified in Familial and Sporadic Medullary Thyroid Carcinoma. The Journal of Clinical Endocrinology & Metabolism, 88(4), 1866-1872. doi:10.1210/jc.2002-021155

Marsh, D. J., Zheng, Z., Arnold, A., Andrew, S. D., Learoyd, D., Frilling, A., . . . Eng, C. (1997). Mutation Analysis of Glial Cell Line-Derived Neurotrophic Factor, a Ligand for an RET/Coreceptor Complex, in Multiple Endocrine Neoplasia Type 2 and Sporadic Neuroendocrine Tumors. The Journal of Clinical Endocrinology & Metabolism, 82(9), 3025-3028. doi:10.1210/jcem.82.9.4197

Martinez-Aguilar, J., Clifton-Bligh, R., & Molloy, M. P. (2016). Proteomics of thyroid tumours provides new insights into their molecular composition and changes associated with malignancy. Sci Rep, 6, 23660. doi:10.1038/srep23660

Martínez-Aguilar, J., Clifton-Bligh, R., & Molloy, M. P. (2015). A multiplexed, targeted mass spectrometry assay of the S100 protein family uncovers the isoform-specific expression in thyroid tumours. BMC Cancer, 15, 199. doi:10.1186/s12885-015-1217-x

McCormack, A., Kaplan, W., Gill, A. J., Little, N., Cook, R., Robinson, B., & Clifton-Bligh, R. (2013). MGMT expression and pituitary tumours: relationship to tumour biology. Pituitary, 16(2), 208-219. doi:10.1007/s11102-012-0406-8

McCormack, A. I., McDonald, K. L., Gill, A. J., Clark, S. J., Burt, M. G., Campbell, K. A., . . . Clifton-Bligh, R. J. (2009). Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clinical Endocrinology, 71(2), 226-233. doi:10.1111/j.1365-2265.2008.03487.x

McDonald, K. L., Ha, W., & Khasraw, M. (2017). P01.20 Treatment of recurrent glioblastoma with the cytokine inhibitor, ibudilast in combination with temozolomide. Neuro-Oncology, 19(suppl_3), iii27-iii27. doi:10.1093/neuonc/nox036.096

McDonald, K. L., Ha, W., & Sevim, H. (2014). MIF-CD74 guided therapeutic strategy for the upfront treatment of GBM patients with an unmethylated MGMT promoter. Neuro-Oncology, 16(Suppl 3), iii4-iii5. doi:10.1093/neuonc/nou206.15

McDonald, K. L., O’Sullivan, M. G., Parkinson, J. F., Shaw, J. M., Payne, C. A., Brewer, J. M., . . . Robinson, B. G. (2007). IQGAP1 and IGFBP2: Valuable Biomarkers for Determining Prognosis in Glioma Patients. Journal of Neuropathology & Experimental Neurology, 66(5), 405-417. doi:10.1097/nen.0b013e31804567d7

Meyer-Rochow, G. Y., Jackson, N. E., Conaglen, J. V., Whittle, D. E., Kunnimalaiyaan, M., Chen, H., . . . Sidhu, S. B. (2010). MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets. Endocrine-Related Cancer, 17(3), 835-846. doi:10.1677/erc-10-0142

Meyer-Rochow, G. Y., Smith, J. M., Richardson, A.-L., Marsh, D. J., Sidhu, S. B., Robinson, B. G., & Benn, D. E. (2009). Denaturing High Performance Liquid Chromatography Detection of SDHB, SDHD, and VHL Germline Mutations in Pheochromocytoma. Journal of Surgical Research, 157(1), 55-62. doi:http://dx.doi.org/10.1016/j.jss.2008.07.043

Mitic, G., Tsoli, M., Ziegler, D. S., & Kavallaris, M. (2013). Abstract 3431: βIII-tubulin in glioblastoma: An emerging multifactorial survival factor role in chemotherapy response and tumor formation. Cancer Research, 73. doi:10.1158/1538-7445.am2013-3431

Mond, M., Bullock, M., Yao, Y., J Clifton-Bligh, R., Gilfillan, C., & J Fuller, P. (2015). Somatic Mutations of FOXE1 in Papillary Thyroid Cancer. Thyroid, 25. doi:10.1089/thy.2015.0030

Nielsen, A., Scarlett, C. J., Samra, J. S., Gill, A., Li, Y., Allen, B. J., & Smith, R. C. (2005). Significant overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma using real-time quantitative reverse transcription polymerase chain reaction. Journal of Gastroenterology and Hepatology, 20(2), 256-263. doi:10.1111/j.1440-1746.2004.03531.x

Parker, N. R., Hudson, A. L., Khong, P., Parkinson, J. F., Dwight, T., Ikin, R. J., . . . Howell, V. M. (2016). Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma. Scientific Reports, 6, 22477. doi:10.1038/srep22477

Parker, N. R., Khong, P., Parkinson, J. F., Howell, V. M., & Wheeler, H. R. (2015). Molecular Heterogeneity in Glioblastoma: Potential Clinical Implications. Frontiers in Oncology, 5, 55. doi:10.3389/fonc.2015.00055

Parkinson, J. F., Wheeler, H. R., Clarkson, A., McKenzie, C. A., Biggs, M. T., Little, N. S., . . . McDonald, K. L. (2008). Variation of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma. Journal of Neuro-Oncology, 87(1), 71-78. doi:10.1007/s11060-007-9486-0

Payne, C. A., Maleki, S., Messina, M., O’Sullivan, M. G., Stone, G., Hall, N. R., . . . McDonald, K. L. (2008). Loss of prostaglandin D2 synthase: a key molecular event in the transition of a low-grade astrocytoma to an anaplastic astrocytoma. Mol Cancer Ther, 7(10), 3420-3428. doi:10.1158/1535-7163.mct-08-0629

Pillai, U., Phillips, K., Wilkins, G., Baxter, R. C., Benn, D. E., Parker, N. R., . . . Marsh, D. J. (2014). Factors that may influence the willingness of cancer patients to consent for biobanking. Biopreserv Biobank, 12(6), 409-414. doi:10.1089/bio.2014.0039

Pozo, K., Castro-Rivera, E., Tan, C., Plattner, F., Schwach, G., Siegl, V., . . . Bibb, J. A. (2013). The Role of Cdk5 in Neuroendocrine Thyroid Cancer. Cancer cell, 24(4), 10.1016/j.ccr.2013.1008.1027. doi:10.1016/j.ccr.2013.08.027

Sandanayake, N. S., Camuzeaux, S., Sinclair, J., Blyuss, O., Andreola, F., Chapman, M. H., . . . Pereira, S. P. (2014). Identification of potential serum peptide biomarkers of biliary tract cancer using MALDI MS profiling. BMC Clin Pathol, 14(1), 7. doi:10.1186/1472-6890-14-7

Sandanayake, N. S., Sinclair, J., Andreola, F., Chapman, M. H., Xue, A., Webster, G. J., . . . Pereira, S. P. (2011). A combination of serum leucine-rich α-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures. British Journal of Cancer, 105(9), 1370-1378. doi:10.1038/bjc.2011.376

Saxby, A., Nielsen, A., Scarlett, C., Clarkson, A., Morey, A., Gill, A., & Smith, R. (2005). Assessment of HER2 Status in Pancreatic Adenocarcinoma: Correlation of Immunohistochemistry, Quantitative Real-Time RT-PCR, and FISH With Aneuploidy and Survival. The American Journal of Surgical Pathology, 29, 1125-1134. doi:10.1097/01.pas.0000160979.85457.73

Scarlett, C. J., Saxby, A. J., Nielsen, A., Bell, C., Samra, J. S., Hugh, T., . . . Smith, R. C. (2006). Proteomic profiling of cholangiocarcinoma: Diagnostic potential of SELDI-TOF MS in malignant bile duct stricture. Hepatology, 44(3), 658-666. doi:10.1002/hep.21294

Scarlett, C. J., Smith, R. C., Saxby, A., Nielsen, A., Samra, J. S., Wilson, S. R., & Baxter, R. C. (2006). Proteomic Classification of Pancreatic Adenocarcinoma Tissue Using Protein Chip Technology. Gastroenterology, 130(6), 1670-1678. doi:http://dx.doi.org/10.1053/j.gastro.2006.02.036

Schnitzler, M., Dwight, T., Marsh, D. J., Gaskin, E. L., & Robinson, B. G. (1995). Quantitation of APC mRNA in Human Tissues. Biochemical and Biophysical Research Communications, 217(2), 385-392. doi:http://dx.doi.org/10.1006/bbrc.1995.2788

Shah, J. S., Gard, G. B., Yang, J., Maidens, J., Valmadre, S., Soon, P. S., & Marsh, D. J. (2017). Combining serum microRNA and CA-125 as prognostic indicators of preoperative surgical outcome in women with high-grade serous ovarian cancer. Gynecologic Oncology. doi:https://doi.org/10.1016/j.ygyno.2017.11.005

Shah, J. S., Soon, P. S., & Marsh, D. J. (2016). Comparison of Methodologies to Detect Low Levels of Hemolysis in Serum for Accurate Assessment of Serum microRNAs. PLOS ONE, 11(4), e0153200. doi:10.1371/journal.pone.0153200

Sidhu, S., Marsh, D. J., Theodosopoulos, G., Philips, J., Bambach, C. P., Campbell, P., . . . Robinson, B. G. (2002). Comparative Genomic Hybridization Analysis of Adrenocortical Tumors. The Journal of Clinical Endocrinology & Metabolism, 87(7), 3467-3474. doi:10.1210/jcem.87.7.8697

Sidhu, S., Martin, E., Gicquel, C., Melki, J., Clark, S. J., Campbell, P., . . . Robinson, B. G. (2005). Mutation and methylation analysis of TP53 in adrenal carcinogenesis. European Journal of Surgical Oncology (EJSO), 31(5), 549-554. doi:http://dx.doi.org/10.1016/j.ejso.2005.01.013

Soon, P. S., Libe, R., Benn, D. E., Gill, A., Shaw, J., Sywak, M. S., . . . Robinson, B. G. (2008). Loss of heterozygosity of 17p13, with possible involvement of ACADVL and ALOX15B, in the pathogenesis of adrenocortical tumors. Ann Surg, 247(1), 157-164. doi:10.1097/SLA.0b013e318153ff55

Soon, P. S. H., Gill, A. J., Benn, D. E., Clarkson, A., Robinson, B. G., McDonald, K. L., & Sidhu, S. B. (2009). Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas. Endocrine-Related Cancer, 16(2), 573-583. doi:10.1677/erc-08-0237

Soon, P. S. H., Tacon, L. J., Gill, A. J., Bambach, C. P., Sywak, M. S., Campbell, P. R., . . . Sidhu, S. B. (2009). miR-195 and miR-483-5p Identified as Predictors of Poor Prognosis in Adrenocortical Cancer. Clinical Cancer Research, 15(24), 7684.

Tacon, L. J., Soon, P. S., Gill, A. J., Chou, A. S., Clarkson, A., Botling, J., . . . Clifton-Bligh, R. J. (2009). The Glucocorticoid Receptor Is Overexpressed in Malignant Adrenocortical Tumors. The Journal of Clinical Endocrinology & Metabolism, 94(11), 4591-4599. doi:10.1210/jc.2009-0546

Tsang, V. H. M., Dwight, T., Benn, D. E., Meyer-Rochow, G. Y., Gill, A. J., Sywak, M., . . . Parker, N. R. (2014). Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours. Endocrine-Related Cancer, 21(3), 415-426. doi:10.1530/erc-13-0519

Xue, A., Chang, J. W., Chung, L., Samra, J., Hugh, T., Gill, A., . . . Smith, R. C. (2012). Serum apolipoprotein C-II is prognostic for survival after pancreatic resection for adenocarcinoma. British Journal of Cancer, 107(11), 1883-1891. doi:10.1038/bjc.2012.458

Xue, A., Gandy, R. C., Chung, L., Baxter, R. C., & Smith, R. C. (2012). Discovery of diagnostic biomarkers for pancreatic cancer in immunodepleted serum by SELDI-TOF MS. Pancreatology, 12(2), 124-129. doi:http://dx.doi.org/10.1016/j.pan.2012.02.009

Xue, A., Scarlett, C., J Jackson, C., Allen, B., & Smith, R. (2008). Prognostic Significance of Growth Factors and the Urokinase-Type Plasminogen Activator System in Pancreatic Ductal Adenocarcinoma. Pancreas, 36, 160-167. doi:10.1097/MPA.0b013e31815750f0

Xue, A., Scarlett, C. J., Chung, L., Butturini, G., Scarpa, A., Gandy, R., . . . Smith, R. C. (2010). Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis. British Journal of Cancer, 103(3), 391-400. doi:10.1038/sj.bjc.6605764

Yeh, J. J., Marsh, D. J., Zedenius, J., Dwight, T., Delbridge, L., Robinson, B. G., & Eng, C. (1999). Fine-structure deletion mapping of 10q22-24 identifies regions of loss of heterozygosity and suggests that sporadic follicular thyroid adenomas and follicular thyroid carcinomas develop along distinct neoplastic pathways. Genes Chromosomes Cancer, 26(4), 322-328.

Zearo, S., Kim, E., Zhu, Y., Zhao, J. T., Sidhu, S. B., Robinson, B. G., & Soon, P. S. (2014). MicroRNA-484 is more highly expressed in serum of early breast cancer patients compared to healthy volunteers. BMC Cancer, 14(1), 200. doi:10.1186/1471-2407-14-200

Zheng, S., Cherniack, A. D., Dewal, N., Moffitt, R. A., Danilova, L., Murray, B. A., . . . Verhaak, R. G. W. (2016). Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell, 29(5), 723-736. doi:10.1016/j.ccell.2016.04.002

Zheng, S., Cherniack, A. D., Dewal, N., Moffitt, R. A., Danilova, L., Murray, B. A., . . . Verhaak, R. (2015). Abstract 2976: Comprehensive Pan-Genomic characterization of adrenocortical carcinoma. Cancer Research, 75(15 Supplement), 2976.

For more information please contact:

Office: (02) 9926 4771

Email: kolling.tumourbanks@sydney.edu.au